texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x

Baylor Charles A. Sammons Research & Clinical Trials

Baylor Charles A. Sammons Cancer Center participates in a wide range of groundbreaking research that is paving the way for new breakthroughs in cancer care. As a Texas Oncology patient, you may be able to take part in these innovative clinical trials.

Innovative Clinical Trial Center (Expand)

Breast Cancer

A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Phase: I/II

Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer

Phase: I

Gastric Cancer

A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Phase: II

Graft-Versus-Host-Disease

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Belumosudil in Black or African American Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

Phase: II

A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Kidney Cancer

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Phase: III

Leukemia

A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Phase: I

Lung Cancer

A Phase III Randomized, Open Label, Multi-Centre, Global Study of Dato-DXd in Combination With Durvalumab and Carboplatin Verses Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-Line Treatment of Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) without Actionable Genomic Alterations (AVANZAR - D926NC00001).

Phase: III

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Phase: III

Lymphomas

A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)

Phase: Ib

Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Phase: I

Miscellaneous

A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

Phase: III

Neuroendocrine Tumors

A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors

Phase: II

Solid Tumors

A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Phase: I/II

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Phase: I

A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination with Pembrolizumab in Patients with Solid Tumors

Phase: I/II

A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRIN

Phase: Ib/II

First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Phase: I

Thrombocytopenia

A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first line steroid treatment (VAYHIT2)

Phase: III

Texas Oncology-Baylor Charles A. Sammons Cancer Center (Expand)

Biliary Cancer

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002) Read Moreabout Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

Phase: II/III

Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC)

An open-label randomized trial of the efficacy and safety of zanidatamab with standard-of-care therapy against standard-of-care therapy alone for advanced HER2-positive biliary tract cancer (JZP598-302) Read Moreabout Ph3 Study of Zanidatamab subjects with HER2+ Bilary Tract Cancer (BTC)

Phase: III

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Bladder Cancer

Ph3 Dura Trem EV MIBC Ca

D910PC00001: A Phase III Randomized Open-Label Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination with Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination with Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle Invasive Bladder Cancer (VOLGA) Read Moreabout Ph3 Dura Trem EV MIBC Ca

Phase: III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Blood Cancer

Ph2 Sub Mosunetuzumab B-cell malig

AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig

Phase: II

Breast Cancer

Ph2 ARX788 HER2 BC T-DMI T-DXd

A Global Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were Previously Treated with T-DXd (ACE-Breast-03) Read Moreabout Ph2 ARX788 HER2 BC T-DMI T-DXd

Phase: II

A Modular Open-Label, Multi-Centre Phase 1/2 Dose-Finding, Optimisation, and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of EP0062 in Patients with Relapsed Locally Advanced or Metastatic AR+/HER2-/ER+ Breast Cancer

Phase: I/II

Observational Study of patients initiating T-Dxd in HER2+ unresectable mBC (RESPOND)

A multi-center multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+ and HER2-low unresectable and/or metastatic breast cancer (DESTINY BREAST- RESPOND) (D9673R00025) Read Moreabout Observational Study of patients initiating T-Dxd in HER2+ unresectable mBC (RESPOND)

Phase: IV

A Phase 1a/1b Study of LOXO-783 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with Advanced Breast Cancer and Other Solid Tumors with a PIK3CA H1047R Mutation

Phase: I

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE)

A Phase 1b/2 Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in Various Combinations in Patients with Metastatic Breast Cancer (ELEVATE) (STML-ELA-0222) Read Moreabout Ph1b/2 Elacestrant + Combo Met Breast Cancer (ELEVATE)

Phase: I/II

Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)

A Phase 3 Open-label Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03)(D926XC00001) Read Moreabout Ph3 Dato Deru +/- Dura tri- BC Lymph nodes (TROPION-Breast03)

Phase: III

Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

A Phase 3 Open-Label Randomized Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive HER2-Negative Advanced Breast Cancer Previously Treated with a CDK4/6 Inhibitor in Combination with Non-Steroidal Aromatase Inhibitor Therapy (VIKTORIA-1) (CELC-G-301) Read Moreabout Ph3 Palb Fulv SOC HR+ HER2- BC CDK4/6 (VIKTORIA-1)

Phase: III

Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)

A Phase 3 Randomized Multi-center Open-label Study of DB-1303 Versus Investigator's Choice Chemotherapy in Human Epidermal Growth Factor Receptor 2 (HER2)-low Hormone Receptor Positive (HR+) Metastatic Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy (ET) (DYNASTY-Breast02) (DB-1303-O-3002) Read Moreabout Ph3 Study of DB1303 in HER2 with mBreast who has progressed Endocrine Therapy (DYNASTY-BREAST02)

Phase: III

PH1b/2 Durva+Pacl mTNBC(Begonia)

A Phase IB/II 2-Stage Open-label Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer (D933LC00001) Read Moreabout PH1b/2 Durva+Pacl mTNBC(Begonia)

Phase: I/II

Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA)

A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT PLUS EVEROLIMUS COMPARED WITH THE PHYSICIAN'S CHOICE OF ENDOCRINE THERAPY PLUS EVEROLIMUS IN PATIENTS WITH ESTROGEN RECEPTOR (ER)-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER (ML43171) Read Moreabout Ph3 Giredes + Everol or Exemes + Everol ER+ HER2- BC (evERA)

Phase: III

Ph3 HER2+/ER+ BC

A PHASE IIIRANDOMIZED OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER (WO43571) Read Moreabout Ph3 HER2+/ER+ BC

Phase: III

Ph3 HER2/neu BC (FLAMINGO-01)

A Randomized Multicenter Placebo-controlled Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects with Residual Disease or High-Risk PCR after both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01) (GLSI-21-01) Read Moreabout Ph3 HER2/neu BC (FLAMINGO-01)

Phase: III

Ph3 Sac Gov Pemb vs PC BC (ASCENT-04)

A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (GS-US-592-6173) Read Moreabout Ph3 Sac Gov Pemb vs PC BC (ASCENT-04)

Phase: III

Ph3 Sac GOv vs PC BC (ASCENT-03)

A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physicians Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors do Express PD-L1 (GS-US-592-6238) Read Moreabout Ph3 Sac GOv vs PC BC (ASCENT-03)

Phase: III

Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

CAMBRIA-2: A Phase III Open-Label Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833 a Next Generation Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients With ER+/HER2- Early Breast Cancer and an Intermediate-high or High risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease (D8535C00001) Read Moreabout Ph3 Adjuvant Endocrine Therapy Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)

Phase: III

Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence (J2J-MC-JZLH) Read Moreabout Ph3 Imlun vs Endo ER+ HER2- BC (EMBER-4)

Phase: III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

FLEX Registry: Evaluate New Gene Express

MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry) Read Moreabout FLEX Registry: Evaluate New Gene Express

Phase 1 pilot study with dose expansion of chemotherapy in combination with CD40 agonist and Flt3 ligand in metastatic triple negative breast cancer

Phase: I

Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01) Read Moreabout Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase: I/II

Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)

SERENA-6: A Phase III Double-blind Randomised Study to Assess Switching to AZD9833 (a Next Generation Oral SERD) + CDK4/6 Inhibitor vs Continuing Aromatase Inhibitor (Letrozole or Anastrozole) + CDK4/6 Inhibitor in HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Disease Progression During 1L Treatment with Aromatase Inhibitor + CDK4/6 Inhibitor Read Moreabout Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-6)

Phase: III

Carcinoid

Ph2 ZN-c3 Uterine Carcinoma

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065) Read Moreabout Ph2 ZN-c3 Uterine Carcinoma

Phase: II

Cervical Cancer

Ph3 robotic Hysterectomy ROCC

(GOG-3043) A Randomized Controlled Trial of Robotic versus Open Radical Hysterectomy for Cervical Cancer (ROCC trial) Read Moreabout Ph3 robotic Hysterectomy ROCC

Phase: III

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Colon Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

Ph2 RO7198457 CRC ctDNA+ Post Resection

A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection

Phase: II/III

Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors

A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001) Read Moreabout Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors

Phase: I

Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST

A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02) Read Moreabout Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST

Phase: I/II

Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX

AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001) Read Moreabout Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX

Phase: I

Ph2 Epidemi Colon Cancer

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001) Read Moreabout Ph2 Epidemi Colon Cancer

Phase: II/III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Read Moreabout Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

Phase: III

Endometrial Cancer

Ph1/2a Narazaciclib + Letrozole 2nd or 3rd LOT Endometrial

A Multi-center Phase 1/2a Study of Narazaciclib (ON 123300) in Combination with Letrozole as Therapy for the Treatment of Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer and other Gynecologic Malignancies (19-02) Read Moreabout Ph1/2a Narazaciclib + Letrozole 2nd or 3rd LOT Endometrial

Phase: I/II

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph3 Selin P53 Endo Carcinoma

A PHASE 3 RANDOMIZED PLACEBO-CONTROLLED DOUBLE-BLIND MULTICENTER TRIAL OF SELINEXOR IN MAINTENANCE THERAPY AFTER SYSTEMIC THERAPY FOR PATIENTS WITH P53 WILD-TYPE ADVANCED OR RECURRENT ENDOMETRIAL CARCINOMA (ENGOT-EN-20/GOG-3083/ XPORT-EC-042) Read Moreabout Ph3 Selin P53 Endo Carcinoma

Phase: III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Esophageal Cancer

Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST

A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02) Read Moreabout Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST

Phase: I/II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Fallopian Tube Cancer

Ph1b TRK-950 Ovarian Peri & Fallopian

A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian

Phase: I

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Ph2 Efficacy & Safety of luveltamab tazebibulin in women w/ovarian (FOLR1)

REFRaME-01: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) versus InvestigatorÂ's Choice (IC) Chemotherapy in Women with Relapsed Platinum resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1) (STRO-002-GM3) Read Moreabout Ph2 Efficacy & Safety of luveltamab tazebibulin in women w/ovarian (FOLR1)

Phase: II

Gall Bladder Cancer

Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

A Phase 2/3 Randomized Controlled Study of CTX-009 in Combination with Paclitaxel versus Paclitaxel Alone in Adult Patients with Unresectable Advanced Metastatic or Recurrent Biliary Tract Cancers who have received One Prior Systemic Chemotherapy Regimen (CTX-009-002) Read Moreabout Ph2/3 CTX-009 + Paclitaxel vs. Paclitaxel in mBiliary Tract

Phase: II/III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Gastric Cancer

Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST

A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02) Read Moreabout Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST

Phase: I/II

A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 when Used in Combination with Ramucirumab and Paclitaxel in Patients with Gastric Cancer

Phase: II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Graft-Versus-Host-Disease

A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Belumosudil in Black or African American Subjects with Chronic Graft Versus Host Disease (cGVHD) After At Least 2 Prior Lines of Systemic Therapy

Phase: II

A Prospective, Observational Cohort Study of Participants at Risk for Chronic Graft-Versus-Host Disease in the United States (THRIVE)

Head and Neck Cancer

Ph1/2 NGM707 mono & combo w/ Pembro in Select Solid Tumors

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NGM707-IO-101) Read Moreabout Ph1/2 NGM707 mono & combo w/ Pembro in Select Solid Tumors

Phase: I/II

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST

A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02) Read Moreabout Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST

Phase: I/II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck

Phase 1/2 dose escalation and cohort expansion study evaluating MCLA-158 (Petosemtamab) as single agent or in combination in advanced solid tumors (MCLA-158-CL01) Read Moreabout Ph1/2 MCLA-158 (Petosemtamab) Mono or + Pembro in Head and Neck

Phase: I/II

Hematologic

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Kidney Cancer

A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma

Phase: III

Leukemia

A Phase 1, open-label, dose-escalation, and dose-expansion study of BMF-500, an oral covalent FLT3 inhibitor, in adults with acute leukemia

Phase: I

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Ph2 Asciminib (ABL001) CP-CML

A Phase II multi-center open-label single-arm dose escalation study of Asciminib monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)(CABL001AUS08) Read Moreabout Ph2 Asciminib (ABL001) CP-CML

Phase: II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph3 LoXO-305/Vene Vene/Ritu BTK CLL-322

LOXO-BTK-20022: A Phase 3 Open-Label Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322) Read Moreabout Ph3 LoXO-305/Vene Vene/Ritu BTK CLL-322

Phase: III

Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060)

Multicohort Study to Customize Ibrutinib Treatment Regimens for Patients with Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (54179060CLL2032) Read Moreabout Ibrutinib Previously Untreated Chronic Lymphocytic Leukemia (TAILOR) (JNJ-54179060)

Phase: II

Liver Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph2 Livmoniplimab Hepatocellular Carcinoma (HCC)

A Phase 2 Randomized Open-Label Study to Evaluate the Optimized Dose Safety and Efficacy of Livmoniplimab in Combination with Budigalimab for locally advanced or Metastatic Hepatocellular Carcinoma (HCC) patients who have progressed after an approved immune checkpoint inhibitor containing regimen in 1L HCC (M24-147) Read Moreabout Ph2 Livmoniplimab Hepatocellular Carcinoma (HCC)

Phase: II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Lung Cancer

STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

A GLOBAL PHASE 3 RANDOMIZED MULTICENTER OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLYADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS (FURVENT) FURMO-004 Read Moreabout STAR Ph3 Furmo v platinum chemo in EXON 20 NSCLC EGFR

Phase: III

Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors

A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001) Read Moreabout Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors

Phase: I

Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3)

A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ONC-005) Read Moreabout Ph1/2 of Quarat Ozeplasmid and Atezolizumab with SCLC (ES-SCLC) (Acclaim-3)

Phase: I/II

Ph1/2 NGM707 mono & combo w/ Pembro in Select Solid Tumors

A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies (NGM707-IO-101) Read Moreabout Ph1/2 NGM707 mono & combo w/ Pembro in Select Solid Tumors

Phase: I/II

STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

A Phase 1/2 Study of Avutometinib (VS-6766) in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203) Read Moreabout STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC

Phase: I/II

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

Ph2 MRTX849 Pembro NSCLC KRAS

A Phase 2 Trial of Adagrasib Monotherapy and in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007) Read Moreabout Ph2 MRTX849 Pembro NSCLC KRAS

Phase: II/III

Ph2 Adagrasib NSCLC KRAS G12C Mutation

A Phase 2 Trial of Combination Therapies with Adagrasib in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-017) Read Moreabout Ph2 Adagrasib NSCLC KRAS G12C Mutation

Phase: II

A Phase III Randomized, Open Label, Multi-Centre, Global Study of Dato-DXd in Combination With Durvalumab and Carboplatin Verses Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-Line Treatment of Patients with Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) without Actionable Genomic Alterations (AVANZAR - D926NC00001).

Phase: III

STAR: PH1/3 Biomarker unresectable stg3 NSCLC

A PHASE I-III MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF PATIENTS SELECTED ACCORDING TO BIOMARKER STATUS WITH LOCALLY ADVANCED UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER (BO42777) Read Moreabout STAR: PH1/3 Biomarker unresectable stg3 NSCLC

Phase: III

STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX) Read Moreabout STAR Ph3 Adj Selp St1B/3 RET+ NSCLC

Phase: III

Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)

A Randomized Controlled Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous NSCLC (HARMONi-3)(SMT112-3003) Read Moreabout Ph3 Multiregional Study of Ivonescimab combined with Pembro for mNSCLC (HARMONi-3)

Phase: III

Ph3 Study of AK112 or Placebo + Pemtrexed & Carboplatin EGFR NSCLC

A Randomized Double-blind Multi-center Phase III Study of AK112 or Placebo Combined with Pemetrexed and Carboplatin in Patients with EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi) (AK112-301) Read Moreabout Ph3 Study of AK112 or Placebo + Pemtrexed & Carboplatin EGFR NSCLC

Phase: III

Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor

A Randomized Open-Label Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (GS-US-626-6216) Read Moreabout Ph3 Zimb Domv vs Pemb NSCLC Lymph Kinase geo Tumor

Phase: III

A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of Taletrectinib in Patients with Advanced or Metastatic ROS1 Positive NSCLC and Other Solid Tumors.

Phase: II

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Phase: III

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

EF-36/Keynote B36: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer

Phase: II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer

Phase 3 Two-stage Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors (PRESERVE-003) Read Moreabout ONC-392 vs. Docetaxel in PD-1 Resistant Non-small Cell Lung Cancer

Phase: III

Phase II Trial of LP-300 in Combination with Carboplatin and Pemetrexed in Never Smoker Patients with Relapsed Advanced Primary AdenoCarcinoma of the Lung After Treatment with Tyrosine Kinase Inhibitors

Phase: II

Lymphomas

A Phase 1b/2, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of a Modified Tafasitamab IV Dosing Regimen Combined with Lenalidomide (LEN) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) (MINDway)

Phase: Ib

Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

A PHASE 1B/3 DOUBLE-BLIND RANDOMIZED ACTIVE-CONTROLLED 3-STAGE BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (EZH-302) Read Moreabout Ph 1b/ 3 Taze w/ R2 R/R Fol Lymph

Phase: I

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II

Ph3 LOXO-305 vs PC of BTK in MCL

A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019) Read Moreabout Ph3 LOXO-305 vs PC of BTK in MCL

Phase: III

Ph2 Sub Mosunetuzumab B-cell malig

AN OPEN-LABEL MULTICENTER PHASE II TRIAL EVALUATING THE SAFETY EFFICACY AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389) Read Moreabout Ph2 Sub Mosunetuzumab B-cell malig

Phase: II

Ph3 LoXO-305/Vene Vene/Ritu BTK CLL-322

LOXO-BTK-20022: A Phase 3 Open-Label Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322) Read Moreabout Ph3 LoXO-305/Vene Vene/Ritu BTK CLL-322

Phase: III

Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Phase: I

Melanoma

Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors

A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001) Read Moreabout Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors

Phase: I

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma

Phase: III

A Phase II randomized study of adjuvant immunotherapy with the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab versus Pembrolizumab only after complete resection of high-risk cutaneous melanoma

Phase: II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Mesothelioma

Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors

A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001) Read Moreabout Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors

Phase: I

Miscellaneous

A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)

Phase: III

An Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects with Relapsed/Refractory Large B Cell Lymphoma (LBCL)

Phase: I/II

Myelodysplastic Syndrome

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Myelofibrosis

A PHASE 1/2 STUDY TO EVALUATE SAFETY AND EFFICACY OF SELINEXOR, A SELECTIVE INHIBITOR OF NUCLEAR EXPORT, IN COMBINATION WITH RUXOLITINIB IN TREATMENT NAÏVE PATIENTS WITH MYELOFIBROSIS

Phase: I/II

Myelomas

Ph3 Sub VS Inta Isatu +Poma Dexa r/r MM

A randomized Phase 3 open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma (RRMM) (EFC15951) Read Moreabout Ph3 Sub VS Inta Isatu +Poma Dexa r/r MM

Phase: III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Neuroendocrine Tumors

A Phase 2 multi-center, open-label, single arm study of nab-sirolimus in patients with well-differentiated neuroendocrine tumors (NETs) of the gastrointestinal tract, lung, or pancreas who have not received prior treatment with mTOR inhibitors

Phase: II

Ovarian Cancer

Ph1b TRK-950 Ovarian Peri & Fallopian

A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian

Phase: I

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST

A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02) Read Moreabout Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST

Phase: I/II

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01) Read Moreabout Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase: I/II

Ph2 Efficacy & Safety of luveltamab tazebibulin in women w/ovarian (FOLR1)

REFRaME-01: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) versus InvestigatorÂ's Choice (IC) Chemotherapy in Women with Relapsed Platinum resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1) (STRO-002-GM3) Read Moreabout Ph2 Efficacy & Safety of luveltamab tazebibulin in women w/ovarian (FOLR1)

Phase: II

Pancreatic Cancer

Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors

A phase 1 study of SGN-BB228 in advanced melanoma and other solid tumors (SGNBB228-001) Read Moreabout Ph1 SGN-BB228 in Adv Melanoma & other Solid Tumors

Phase: I

SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX)

A PHASE II RANDOMIZED OPEN-LABEL TRIAL OF NAB-PACLITAXEL +GEMCITABINE WITH OR WITHOUT BOTENSILIMAB (Agen1181) IN PATIENTS WITH METASTATIC PANCREATIC CANCER WHO HAVE PROGRESSED ON PRIOR 5FU + LEUCOVORIN+ IRINOTECAN +OXALIPLATIN (FOLFIRINOX) Read Moreabout SCRI:GI 348 :Ph1b/2 NabPac+ Gem +/- Botens Pancreatic 5FU +leuc Irin Oxal (FOLFIRINOX)

Phase: I/II

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01) Read Moreabout Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase: I/II

Peritoneal Cancer

Ph1b TRK-950 Ovarian Peri & Fallopian

A Phase 1b Multicenter Study to Determine the Dose Safety Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors.(950P1V02) Read Moreabout Ph1b TRK-950 Ovarian Peri & Fallopian

Phase: I

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian Fallopian Tube or Primary Peritoneal Cancer (ZN-c3-005 GOG 3066) Read Moreabout STAR Ph2 ZN-c3 Tumor DNA Repair CCGA

Phase: II

Ph2 Efficacy & Safety of luveltamab tazebibulin in women w/ovarian (FOLR1)

REFRaME-01: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) versus InvestigatorÂ's Choice (IC) Chemotherapy in Women with Relapsed Platinum resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1) (STRO-002-GM3) Read Moreabout Ph2 Efficacy & Safety of luveltamab tazebibulin in women w/ovarian (FOLR1)

Phase: II

Prostate Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

Ph3 Apalutamide Monotherapy Castration-Sensitive Prostate Cancer (mCSPC) LIBERTAS

A Phase 3 Open-label Randomized Prospective Study of Apalutamide with Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) following PSA Response in Participants with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) (56021927PCR3020) Read Moreabout Ph3 Apalutamide Monotherapy Castration-Sensitive Prostate Cancer (mCSPC) LIBERTAS

Phase: III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors (NUV-868-01) Read Moreabout Ph1/2 FIH NUV-868 Olap or Enzal Select Solids

Phase: I/II

Rectal Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

Ph2 RO7198457 CRC ctDNA+ Post Resection

A multi-site open-label Phase II randomized controlled trial to compare the efficacy of RO7198457 versus watchful waiting in resected Stage II (high risk) and Stage III colorectal cancer patients who are ctDNA positive following resection (BNT122-01) Read Moreabout Ph2 RO7198457 CRC ctDNA+ Post Resection

Phase: II/III

Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX

AN OPEN-LABEL MULTICENTER PHASE 1a/1b STUDY OF IGM-8444 AS A SINGLE AGENT AND IN COMBINATION IN SUBJECTS WITH RELAPSED REFRACTORY OR NEWLYDIAGNOSED CANCERS (IGM-8444-001) Read Moreabout Ph1 FIH IGM-8444 r/r Select Solid & New Cancer DX

Phase: I

Ph2 Epidemi Colon Cancer

Epidemiological study to determine the prevalence of ctDNA positivity in participants with Stage II (high risk) or Stage III CRC after surgery with curative (R0) intent and subsequent adjuvant chemotherapy with monitoring of ctDNA during clinical follow-up (BNT000-001) Read Moreabout Ph2 Epidemi Colon Cancer

Phase: II/III

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

SGNTUC-029: An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Read Moreabout Ph3 Tuc+Trast&mFF6 v mFF6 mCRC (MOUNTAINEER-03)

Phase: III

Renal Cancer

Ph1b-XL092 Immun Onco mST

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors (XL092-002) Read Moreabout Ph1b-XL092 Immun Onco mST

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Skin Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Solid Tumors

A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies

Phase: I/II

A Multicenter, Open label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial

Phase: III

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-1660 in Participants with Solid Tumors.

Phase: I

STAR Ph1/2 MRTX849 Solids KRAS G12C

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001) Read Moreabout STAR Ph1/2 MRTX849 Solids KRAS G12C

Phase: I/II

A Phase 1/2, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of NDI-101150 Administered as Monotherapy or in Combination with Pembrolizumab in Patients with Solid Tumors

Phase: I/II

A PHASE 1/2A OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY TO INVESTIGATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF MIRDAMETINIB IN COMBINATION WITH BGB-3245 IN PATIENTS WITH ADVANCED SOLID TUMORS

Phase: I/II

Ph1b/2 BEMA FGFR2b ST Basket Trial

A Phase 1b/2 Multicenter Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression (FORTITUDE-301) (20210104) Read Moreabout Ph1b/2 BEMA FGFR2b ST Basket Trial

Phase: I/II

Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST

A PHASE 1B/2 OPEN-LABEL SAFETY TOLERABILITY AND EFFICACY STUDY OF NC410 PLUS PEMBROLIZUMAB FOR PARTICIPANTS WITH ADVANCED UNRESECTABLE AND/OR METASTATIC IMMUNE CHECKPOINT INHIBITOR (ICI) REFRACTORY SOLID TUMORS OR ICI NAIVE MSS/MSI-LOW SOLID TUMORS (NC410-02) Read Moreabout Ph1b/2 NC410+ Pembro ICI refrac ST MSS/MSI low ST

Phase: I/II

A PHASE 1B/2, OPEN-LABEL, MULTICENTER, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07220060 IN COMBINATION WITH PF-07104091 PLUS ENDOCRIN

Phase: Ib/II

STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes (TSC-007) Read Moreabout STAR Ph2 Basket nab-siro Solids TSC1 or TSC2 genes

Phase: II

Ph2 Bren Vedo + Pembro ST prior PD-1

A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies (SGN35-033) Read Moreabout Ph2 Bren Vedo + Pembro ST prior PD-1

Phase: II

First-in-Human Study of STX-478, a Mutant-Selective PI3K? Inhibitor as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumor

Phase: I

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Thrombocytopenia

A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or relapsed after first line steroid treatment (VAYHIT2)

Phase: III

A phase 3, randomized, double-blind, study of ianalumab (VAY736) versus placebo in addition to first-line corticosteroids in primary immune thrombocytopenia (VAY736I12301)

Phase: III

Thyroid Cancer

CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Harbinger Health Collection of Blood and Tissue Samples from Cancer and Non-Cancer Subjects for Validation of a Novel Blood-Based Multi-Cancer Screening Test (HH-PRT-0001) Read Moreabout CORE HH Cancer ORigin Epigenetics Sample Collection Screening Test

Phase: IV

Urothelial Cancer

STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of brigimadlin (BI 907828) for treatment of patients with locally advanced/ metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours. (1403-0011) Read Moreabout STAR Ph2/3 BI 907828 MDM2 TP53 WT Select Solids (Brightline-2)

Phase: II/III

Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

JZP898-101: A Phase 1 first-in-human open-label multicenter study of JZP898 as monotherapy and in combination with pembrolizumab in participants with advanced or metastatic solid tumors Read Moreabout Ph1 FIH JZP898 +/- PD-1/PD-L1 with met Solid Tumors

Phase: I

Uterine Cancer

Ph2 ZN-c3 Uterine Carcinoma

A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women with Recurrent or Persistent Uterine Serous Carcinoma (ZN-c3-004 GOG 3065) Read Moreabout Ph2 ZN-c3 Uterine Carcinoma

Phase: II

Waldenström macroglobulinemia

STAR: Zanu in Acala intolerant B-Cell

A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215) Read Moreabout STAR: Zanu in Acala intolerant B-Cell

Phase: II